eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 68
Original paper

Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease

Maciej Kajor, Michał Kukla, Marek Waluga, Łukasz Liszka, Michał Dyaczyński, Grzegorz Kowalski, Dominika Żądło, Agnieszka Berdowska, Mateusz Chapuła, Anna Kostrząb-Zdebel, Rafał J. Bułdak, Tomasz Sawczyn, Marek Hartleb

Pol J Pathol 2017; 68 (2): 117-127
Online publish date: 2017/09/01
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The aim of this study was to investigate hepatic chemerin mRNA, serum chemerin concentration, and immunohistochemical staining for chemerin and and chemokine receptor-like 1 (CMKLR1) in hepatic tissue in 56 morbidly obese women with nonalcoholic fatty liver disease (NAFLD) and to search for a relationship with metabolic and histopathological features.

Chemerin mRNA was assessed by quantitative real-time PCR, chemerin, and CMKLR1 immunohistochemical expression with specific antibodies, while serum chemerin concentration was assessed with commercially available enzyme-linked immunosorbent assays.

Serum chemerin concentration reached 874.1 ±234.6 ng/ml. There was no difference in serum chemerin levels between patients with BMI < 40 kg/m2 and ≥ 40 kg/m2. Serum chemerin concentration tended to be higher in patients with hepatocyte ballooning, greater extent of steatosis, and definite nonalcoholic steatohepatitis (NASH). Liver chemerin mRNA was observed in all included patients and was markedly, but insignificantly, higher in those with BMI ≥ 40 kg/m2, hepatocyte ballooning, greater extent of steatosis, and definite NASH.

Hepatic chemerin mRNA might be a predictor of hepatic steatosis, hepatocyte ballooning, and NAFLD activity score (NAS) but seemed not to be a primary driver regulating liver necroinflammatory activity and fibrosis. The lack of association between serum chemerin and hepatic chemerin mRNA may suggest that adipose tissue but not the liver is the main source of chemerin in morbidly obese women.

chemerin, chemokine receptor-like 1, adipokine, liver, nonalcoholic fatty liver disease

Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011; 17: 2801-2811.
Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147: 754-764.
Ziółkowski A, Wyleżoł M, Kukla M, et al. The Comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric surgery. Obes Surg 2005; 15: 1309-1314.
Friis-Liby I, Aldenborg F, Jerlstad P, et al. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2004; 39: 864-869.
Kukla M, Mazur W, Bułdak RJ, Mazur W. Potential role of leptin, adiponectin and three novel adipokines visfatin, chemerin and vaspin in chronic hepatitis. Mol Med 2011; 17: 1397-1410.
MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell Metab 2007; 6: 159-161.
Roh S, Song S, Choi K, et al. Chemerin – a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007; 362: 1013-1018.
Wittamer V, Franssen J, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977-985.
Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
Moretta A, Marcenaro E, Parolini S, et al. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008; 15: 226-233.
Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinol 2007; 148: 4687-4694.
Goralski KB, McCarthy TC, Hanniman EA et al. Chemerin a novel adipokine that regulates adipogenesis and adipocyte metabolizm. J Biol Chem 2007; 282: 28175-28188.
Takahashi M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008; 582: 573-578.
Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005; 280: 34661-34666.
Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol 2010; 72: 342-348.
Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J Exp Med 2008; 205: 2187-2190.
Stejskal D, Karpisek M, Hanulova Z, et al. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 217-221.
Ernst MC, Sinal CJ Chemerin: At the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010; 21: 660-667.
Kukla M, Żwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010; 45: 235-242.
Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46: 91-97.
Yilmaz Y, Kurt R, Gurdal A, et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 2011; 217: 125-129.
Kukla M, Berdowska A, Gabriel A, et al. Association between hepatic angiogenesis and serum adipokine profile in non-obese chronic hepatitis C patients. Pol J Pathol 2011; 62: 218-228.
Kukla M, Adamek B, Waluga M, et al. Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C. Biomed Res Int 2014; 2014: 517820.
Döcke S, Lock JF, Birkenfeld AL, et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol 2013; 169: 547-557.
Krautbauer S, Wanninger J, Eisinger K, et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol 2013; 95: 199-205.
Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolizm. Cytokine Growth Factor Rev 2011; 22: 331-338.
Vermi W, Riboldi E, Wittamer V, et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 2005; 201: 509-515.
Muruganandan S, Parlee SD, Rourke JL, et al. Chemerin, a novel peroxisome proliferator-activated receptor (PPAR) target gene that promotes mesenchymal stem cell adipogenesis. J Biol Chem 2011; 286: 23982-23995.
Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009; 58: 2731-2740.
Wanninger J, Bauer S, Eisinger K, et al. Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. Mol Cell Endocrinol 2012; 349: 248-254.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
Kukla M, Żwirska-Korczala K, Gabriel A, et al. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat 2010; 17: 661-667.
Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric burgery. J Clin Endocrinol Metab 2010; 95: 2892-2896.
Cash JL, Hart R, Russ A, et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008; 205: 767-775.
Tan BK, Chen J, Farhatullah S, et al. Insulin and adipose tissue chemerin. Diabetes 2009; 58: 1971-1977.
Bauer S, Bala M, Kopp A, et al. Adipocyte chemerin release is induced by insulin without being translated to higher levels in vivo. Eur J Clin Invest 2012; 42: 1213-1220.
Neumann M, Meier EM, Rein-Fischboeck L, et al. Chemokine-Like Receptor 1 mRNA weakly correlates with non-alcoholic steatohepatitis score in male but not female individuals. Int J Mol Sci 2016; 17 (8) pii: E1335.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe